Sumitovant Biopharma Ltd. has officially acquired Myovant Sciences Ltd.   The deal was originally announced October 23, 2022.  Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total transaction value of almost $1.7 billion. “We are excited to have officially completed our acquisition of Myovant and look forward to working together to address unmet needs in women’s health and prostate cancer,” said Myrtle ...